A Covalent Resveratrol‐Polyoxometalate Hybrid for Synergistic Disassembly of Prion Protein Fragment 106–126 Aggregates and Catalytic Scavenging of Reactive Oxygen Species

Why It Matters

The dual‑action platform tackles two core drivers of prion neurodegeneration—protein aggregation and oxidative stress—offering a promising therapeutic avenue that could outperform conventional antioxidants.

Key Takeaways

• Res-MnMo6 disassembles 93% of PrP106‑126 aggregates.
• Catalytically scavenges superoxide and hydroxyl radicals.
• Covalent resveratrol graft creates sustainable antioxidant cycle.
• Electronic redistribution lowers kinetic barriers in ROS reactions.
• Reduces cytotoxicity and oxidative damage in cell models.

Pulse Analysis

Prion diseases, such as Creutzfeldt‑Jakob disease, are characterized by the misfolding and aggregation of the prion protein, which triggers relentless neurodegeneration. In parallel, persistent oxidative stress amplifies neuronal injury, creating a feedback loop that accelerates disease progression. Traditional therapeutic strategies have focused on either inhibiting protein aggregation or quenching reactive oxygen species (ROS), but rarely both, limiting clinical efficacy. A combined approach that addresses these intertwined pathologies is therefore a critical unmet need in neuro‑degenerative research.

The newly reported Res‑MnMo6 hybrid bridges organic and inorganic chemistry by covalently attaching a resveratrol‑derived ligand to an Anderson‑type polyoxometalate (POM) cluster. This design repurposes the antioxidant properties of resveratrol into a catalytic framework, allowing continuous ROS neutralization rather than one‑time sacrificial consumption. The hybrid’s electronic structure is tuned so that the POM scaffold lowers activation energies for both superoxide (·O2‑) and hydroxyl (·OH) scavenging steps, delivering a long‑lasting redox cycle. In vitro, Res‑MnMo6 disassembles 93% of pre‑formed PrP106‑126 aggregates and markedly reduces cell toxicity, demonstrating that the covalent linkage translates into functional synergy.

The implications extend beyond prion disorders. By proving that covalent organic‑inorganic hybrids can deliver sustained antioxidant activity while dismantling pathogenic protein assemblies, this work opens a pathway for next‑generation neuroprotective agents. Pharmaceutical pipelines may adopt similar hybrid architectures to target amyloid‑β, α‑synuclein, or tau aggregates, where oxidative stress also plays a pivotal role. Moreover, the catalytic ROS‑scavenging mechanism could inspire broader applications in inflammation, ischemia‑reperfusion injury, and aging‑related oxidative damage, positioning Res‑MnMo6 as a template for multifunctional therapeutics.